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There is no standard treatment for patients with pleural malignancies. The aim of this prospective study was to investigate the toxicity
and long-term results of a multimodality treatment consisting of surgery and intrathoracic chemohyperthermia (ITCH) for the
treatment of patients with pleural malignancies. From January 1990 to August 2000, 24 patients with mesothelioma (n¼17),
fibrosarcoma (n¼3), pleural adenocarcinoma (n¼3) and thymoma (n¼1) were included. The mesothelioma stages were T1 or T2
in 10 cases, and T3 or T4 in seven cases. After cytoreductive surgery, ITCH was carried out for over 60min, at inflow temperatures
less than 451C, either with mitomycin C (n¼7) or cisplatin (n¼5) or both (n¼12). One patient died from major thoracic air leaks
after major decortication and pleurectomy. Seven patients had complications, one pleural clotting necessitating reoperation. After a
median follow-up of 89 months, the overall 1-year and 5-year survival rates were 74 and 27%, respectively. For T1 and T2
mesothelioma patients, the median survival was 41.3 months, and for T3 and T4 tumours, it was 4.5 months (P¼0.001). The
fibrosarcoma patients are alive with no evidence of recurrence at 24, 43 and 54 months. In the conclusion, the combination of surgery
with ITCH with mitomycin and/or cisplatin is relatively safe. This procedure may offer unexpected long-term survival in a selected
group of patients (T1 and T2 mesothelioma patients and fibrosarcoma patients).
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Malignant pleural effusion or mesothelioma has appeared
increasingly in the last two decades. In France, in 1992, the
frequency of mesothelioma was evaluated at 600 new cases each
year (Boutin et al, 1997). Nevertheless, the prognosis is unfavour-
able with or without treatment (survival rate from 6 to 16 months).
Many multimodality treatment programmes combining cytore-
ductive surgery, radiotherapy, chemotherapy and many experi-
mental treatments such as photodynamic therapy, immunotherapy
and gene therapy have been used (Sterman et al, 1999), but there is
no standard treatment for these malignancies. Local treatment with
antitumour drugs offers a theoretic advantage: the tumour is
exposed directly to higher drug concentrations, whereas a lower
incidence of toxic side effects may be expected. Combining the
local effect of intrapleural chemotherapy with hyperthermia may
offer an additional benefit: the effect of heat on cytotoxicity,
demonstrated in vitro at temperatures over 42.51C (Crile, 1963);
the synergistic effect of heat and chemotherapy on certain drugs
like mitomycin C (MMC) and cisplatin (CDDP) (Barlogie et al,
1980; Teicher et al, 1981). We had already reported a phase I study
on the combination of surgery, intrathoracic intrapleural che-
motherapy and intrapleural hyperthermia (ITCH) for diffusive
malignant pleural effusions (Carry et al, 1993). The feasibility, the
toxicity and the preliminary results of this combined management
were also reported by other teams (Matsuzaki et al, 1995;
Markman, 1997; Yellin et al, 2001). The objective of this
prospective study was to evaluate the toxicity and long-term
results of this multimodality therapy, which was given simulta-
neously to patients with various pleural malignancies.
PATIENTS AND METHODS
Protocol
The inclusion criteria were: (a) patients with diffusive malignant
pleural disease; (b) no evidence of spread beyond the involved
hemithorax or patients without extrathoracic metastasis;
(c) cardiorespiratory function sufficient to allow the required
resection; and (d) signed informed consent. The exclusion criteria
were: (a) patients older than 75 years; (b) renal or myocardial
failures; (c) central nervous system disease (vascular or neoplas-
tic); and (d) WHO index 42. Malignant pleural diseases were
found during thoracoscopy for preoperative cytological and
histological evaluations. Patients had a complete preoperative
history and physical examination, complete blood count, liver
function tests, renal function tests, electrocardiogram, chest X-ray
and computed tomography (CT) scan. All patients had pulmonary
function tests and echocardiogram.
The procedure was realised under general anaesthesia, lateral
position and one lung ventilation. A thoracotomy was performed
to explore the pleural cavity, take cytological and histological
samples, and for pleurectomy and/or decortication and/or wedge
resection when possible. Before the surgical procedure, a
Swan–Ganz catheter was inserted inside the pulmonary artery to
monitor central temperature and haemodynamic parameters. A
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l‘pre-hyperthermia’ hypothermia (under 331C) was realised by
means of ice-bags, cold wraps on the legs (Spenco Ltd, Teynning,
UK) and cooling-hat (Pinopharma, Freudenstadt, Germany to
reduce the rise in systemic temperatures when the hyperthermic
chemotherapy was given. The extent of surgery was tailored
according to the disease and the patient’s condition. Maximal
attempts were made to remove all macroscopic tumour. Before
closure of the thoracotomy, the equipment needed for ITCH was
inserted into the pleural cavity: (a) one 30 French silicone
drainage, inflow drainage (William Harvey, Bard Cardiopulmonary
Division, USA), inserted at the top of the cavity; and (b) one 30
French silicone drainage, outflow drainage (William Harvey),
inserted at the bottom. Thermic probes (Mallinkrodt SA and Cain
SA, Lozanne, France) were also inserted: (a) in the pleural cavity;
(b) one on the inflow and one on the outflow drainage (8–10cm
from the skin); and (c) one in the pericardiac space. Then
thoracotomy was closed and the inflow and outflow drainages were
connected to a sterile close circuit where 4l of perfusate (Travenol
Laboratory, Norfolk, England) was propelled by means of a roller
pump (Cobe) at the rate of 200cm
3min
 1. The perfusate contained
0.7mgkg
 1 (maximum dose of 60mg) of MMC (Kyowa, Tokyo,
Japan) and/or 1mgkg
 1 (maximum dose of 80mg) of CDDP. This
liquid was heated through a thermic exchanger (Dideco, France)
connected to a heating circuit. Intra- and extrapleural thermic
probes were connected to the thermic reader (Cain SA, Lozanne,
France) to be monitored each 10min.
ITCH was carried out for over 60min, paying close attention to
respiratory and haemodynamic functions. The mean maximal
inflow temperature was less than 451C. During ITCH, blood
samples were taken every 30min to determine white cell, red cell
and platelet counts, coagulation, creatinine phosphokinase (CPK),
serum proteins, CRP, lactate acid and haematosis. Mitomycin C
and CDDP levels in blood and perfusate were also measured. After
ITCH, all the patients were placed in the intensive care unit where
these differences were also determined during 1 day.
Follow-up was performed at 1 month and every 3 months in the
outpatient clinic. Computed tomography scans were performed
every 6 months or when a recurrence was suspected. The follow-up
was updated on January 2002.
Patients
From January 1990 to August 2000, 24 patients underwent an
operation combined with ITCH with MMC and/or CDDP. From
January 1990 to October 1995, ITCH was performed with MMC for
mesothelioma and with CDDP for metastatic carcinoma. After the
feasibility study (Carry et al, 1993), ITCH was performed with both
for each type of tumour from November 1995 to August 2000. One
patient underwent a second procedure. There were 17 males and
seven females. Patients’ ages ranged from 27 to 73 years (mean, 59
years). The underlying conditions were diffuse malignant me-
sothelioma in 17 patients, metastatic carcinoma in three patients
(squamous of unknown origin in one patient and adenocarcinoma
of unknown origin in two patients), fibrosarcoma in three patients
and thymoma in one patient. The mesothelioma stages were T1 in
five cases, T2 in five cases, T3 in six cases and T4 in one case,
according to the New International Staging System (International
Mesothelioma Interest Group, 1995).
Surgery consisted of decortication with pleurectomy in 11
patients, pleurectomy in seven patients, wedge resection with
pleurectomy in two patients, resection of tumour with pleurectomy
in three patients and explorative thoracotomy in one patient
(unresectable tumour) (Table 1). Mediastinal lymph node sam-
pling was taken in one mesothelioma patient and was negative. No
adjuvant radiotherapy was performed. One 62-year-old patient
with a T1 fibrosarcoma underwent a second procedure for local
recurrence – pleurectomy and ITCH – 41 months after the first
procedure. The resection margins of the initial resection were not
involved.
Statistical analysis
Data were collected and analysed on a commercially available
program (Staview 4.5, Abacus Inc., Berkeley, CA, USA) and are
expressed as mean, standard deviation (s.d.), median and range.
The two-tailed Student’s t-test was used to take into account
differences in the mean survival of the different groups. The log-
rank and Kaplan–Meier tests were used for analysis of the
censored survival rates.
Table 1 Patient data in chronological order
Age
(years) Gender Diagnosis Stage Surgery Drugs Complications
Site of
recurrence Outcome
Time to
outcome (months)
71 M Mesoth T3 Exploration MMC Hepatic Dead 4
42 M Meta Ca M1 Pleurectomy MMC Air leak Bones Dead 74
72 M Mesoth T2 Pleurectomy MMC Bleeding — Dead 28
65 M Mesoth T2 Decortication+pleurect MMC Local Dead 12
49 M Meta Ca M1 Pleurectomy CDDP Local Dead 20
65 M Meta Ca M1 Wedge+pleurectomy CDDP Bleeding Local Dead 6
64 M Mesoth T1 Pleurectomy MMC Local Dead 42
67 F Mesoth T1 Decortication+pleurect MMC — Alive 93
62 M Mesoth T2 Decortication+pleurect MMC Local Dead 5
45 F Mesoth T1 Pleurectomy MMC Local Dead 41
41 M Mesoth T3 Pleurectomy MMC–CDDP Fever — Dead 4
66 M Mesoth T3 Decortication+pleurect MMC–CDDP Bones Dead 5
70 M Mesoth T3 Pleurectomy MMC–CDDP Local Dead 12
62 M Mesoth T1 Wedge+pleurectomy MMC–CDDP Local Dead 43
62 F Fibrosarc T1 Resection+pleurect MMC–CDDP — Alive 54
50 M Mesoth T2 Decortication+pleurect MMC–CDDP Bones Dead 38
54 F Thymoma T1 Decortication+pleurect MMC–CDDP — Alive 56
27 F Fibrosarc T1 Resection+pleurect MMC–CDDP — Alive 43
62 M Mesoth T4 Decortication+pleurect MMC–CDDP Air leak — Dead Postop.
67 F Mesoth T3 Decortication+pleurect MMC–CDDP Local Dead 17
54 M Mesoth T3 Decortication+pleurect MMC–CDDP Wound sepsis Local Dead 16
61 F Fibrosarc T3 Resection+pleurect MMC–CDDP — Alive 24
61 M Mesoth T1 Decortication+pleurect MMC–CDDP Local Alive 23
73 M Mesoth T2 Decortication+pleurect MMC–CDDP Wound sepsis Local Alive 18
Mesoth¼mesothelioma; Meta Ca¼metastatic carcinoma; Fibrosarc¼fibrosarcoma; pleurect¼pleurectomy; MMC¼mitomycin C; CDDP¼cisplatin; Postop.¼postoperative.
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Thermic, biological and pharmacokinetic results
No technical problems and no thermal intolerance occurred.
Neither haemodynamic instability nor respiratory instability was
noticed. The maximal inflow temperature observed was 48.21C.
The mean maximal intrapleural temperature was 42.21C (s.d. 0.7,
range 40.5–43.0) and the mean maximal temperature in the
pulmonary artery was 38.21C (s.d. 0.8, range 37.0–39.1). In all
patients, the temperature in the pulmonary artery dropped to
normal values within 2–7h after the end of ITCH. The blood levels
of MMC and CDDP never reached the systemic toxic level
(1mgml
 1) on the day of ITCH and were immeasurable on the
first postoperative day. There was no renal or haematological
toxicity. Haemoglobin dropped by 2 points on average and total
proteins by 20gl
 1 (s.d. 7.1). Creatinine phosphokinase increased
to about 1000 IU (s.d. 366) and CRP to about 20mgl
 1 (s.d. 20) on
the first postoperative day.
Clinical results
The mean postoperative hospital stay was 13 days (range 9–29).
The single operative mortality (hospital 30-day mortality) was
related to complications secondary to major thoracic air leaks, on
the 15th postoperative day, after extensive decortication and
pleurectomy for the treatment of a T4 mesothelioma. Six
additional patients had surgical complications: an aeric leak
occurred in a 42-year-old man resulting in his hospital discharge
being somewhat delayed; pleural clotting occurred in two patients
necessitating surgery in one case before recovery; wound abscesses
occurred in two patients without necessitating new surgery; and
one patient presented a prolonged hyperthermia syndrome with-
out bacteriological standpoint documentation.
No complication occurred after the second procedure for the
patient who presented a local recurrence of fibrosarcoma. No late
complications were observed.
Survival results
The median follow-up was 89 months (range 23–149). Seven
patients are still alive at 18–93 months after the surgery. There is
no evidence of ipsilateral pulmonary or pleural disease in five
survivors regardless of disease type. The 1-, 2-, 3- and 5-year
actuarial survival rates were 74, 56, 51 and 27%, respectively. The
overall median survival was 21 months. Among 16 patients who
died at follow-up, the first site of disease recurrence could not be
identified with certainly in most patients. In 11 patients, the
disease recurred or progressed in the treated pleura and was the
main cause of death in seven patients, whereas three patients
succumbed to multiorgan metastases and one succumbed to
contralateral pleural involvement. In three patients, bone metas-
tasis was the first site of recurrence and patients succumbed to
multiorgan metastases. All pleural recurrences were diagnosed on
CT scan. Bone metastasis were diagnosed on bone scintigraphy.
Two patients died with no evidence of recurrence: one from
pneumonia at 4 months and one from septic shock of digestive
origin. The 1-, 2-, 3- and 5-year actuarial disease-free survival rates
were 64, 50, 28 and 21%, respectively. The median disease-free
survival was 18 months. No significant difference was found
between patients treated with MMC, CDDP or both.
In patients with mesothelioma, the 1-, 2-, 3- and 5-year actuarial
survival rates were 69, 50, 42 and 8%, respectively (Figure 1). The
overall median survival was 18 months. The median survivals of
mesothelioma patients with T1 or T2 stage and with T3 or T4 stage
were 41.3 and 6 months, respectively (P¼0.001). The 1- and 3-year
actuarial survival rates for patients with T1 or T2 stage were 80 and
53.3%, respectively (Figure 2). The 1-year survival rate was 50% for
patients with T3 or T4 stage with no patient alive at 2 years.
In patients with other pleural malignancies, the overall median
survival was 33 months. The patient with thymoma is alive with no
evidence of recurrence, 56 months after the procedure. The three
patients with fibrosarcoma are alive with no evidence of recurrence
at 24, 43 and 54 months but after a second procedure for
recurrence in one case. The three patients with metastatic
carcinoma died from local recurrence in two cases (at 6 and 20
months) and from bone metastases in one case at 74 months.
DISCUSSION
Patients with malignant pleural disease, either metastatic or
primary (mesothelioma), have a poor prognosis, with an average
survival of patients with pleural metastasis which is inferior to
6 months. The median survival reported for patients with
mesothelioma ranges from 6 to 16 months. Multimodality
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Figure 2 Actuarial survival (Kaplan–Meier method) of mesothelioma
patients with T1 or T2 tumours and with T3 or T4 tumours after surgery,
intrathoracic intrapleural chemotherapy and intrapleural hyperthermia.
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Figure 1 Actuarial survival (Kaplan–Meier method) of patients with
mesothelioma and other pleural malignancies after surgery, intrathoracic
intrapleural chemotherapy and intrapleural hyperthermia.
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lapproaches have been of some benefit in prolonging the survival of
very highly selected subgroups of patients, but they have had a
relatively small impact on the majority of patients diagnosed with
this disease (Sterman et al, 1999). Recently, peritoneal carcino-
matosis has been treated by cytoreductive surgery and intraper-
itoneal chemohyperthermia (IPCH), with interesting results in
many specialised teams (Glehen et al, 2002). Radical resection or
cytoreductive procedure seems to prolong survival (Sugarbaker
et al, 1999) and locoregional chemohyperthermia offers many
theorical advantages. The efficacy of hyperthermia against
malignant cells has been demonstrated (Crile, 1963). On the other
hand, hyperthermia has the potential to modify the cytotoxicity of
anticancer drugs and to convert some other drugs to cytotoxic
agents having no considerable toxicity at normal temperatures.
Mitomycin C cytotoxicity, as for CDDP, was found to be enhanced
by heating at 41–421C for 1h (Barlogie et al, 1980; Teicher et al,
1981). Moreover, local chemotherapy may have the advantage of
exposing the tumour directly to higher drug concentrations and
causing less toxic systemic effects. Our experience of IPCH shows
that the device is safe and reliable for patients with peritoneal
carcinomatosis, so we tried this method in the pleural cavity (Gilly
et al, 1999). We choose MMC and CDDP because their antitumor
effects and intraperitoneal or pleural pharmacokinetics are highly
predictable and have been studied most extensively (Rusch et al,
1999; Matsuzaki et al, 1995; Hettinga et al, 1997; Ratto et al, 1999).
The maximum dose of MMC and CDDP was 60mg (0.7mgkg
 1)
and 80mg (1 mgkg
 1), respectively. With these doses, the systemic
drug concentrations never reached the systemic toxic level and
were lower than during IPCH (Carry et al, 1993). This difference
could be explained by the lower absorption capacity of the pleural
membrane and by the enhanced local tissue concentrations after
hyperthermic perfusion (Ratto et al, 1999). It may explain the good
tolerance of this treatment. Other authors used higher doses of
CDDP (80–100mgm
 2) for intrapleural chemohyperthermia, and
they did not report renal or haematological toxicity (Yellin et al,
2001).
The reported study confirms that the combination of surgery
and ITCH is feasible and relatively safe with mortality and
morbidity rates, which did not exceed 4 and 25%. Recently, The
Netherlands Cancer Institute reported mortality and morbidity
rates of 0 and 47%, respectively, after treatment of 14 patients with
pleural malignancies by cytoreductive surgery and ITCH with
CDDP and adriamycin (De Bree et al, 2002). Moreover, in a
previously published study of 26 patients treated with the same
combined treatment (CDDP alone for ITCH), the mortality and
morbidity rate did not reached 4 and 31%, respectively (Yellin et al,
2001). Hence, in all the studies reporting ITCH procedures, only
two postoperative deaths occurred: one due to a technical problem
and one due to a massive aeric leak after extended decortication
and pleurectomy for a T4 mesothelioma, which was certainly not a
good indication. We did not observe empyema, which mainly
occurred in patients who underwent pneumonectomy (not
performed in our study). Its incidence seems to be enhanced
by radiation, hyperthermia and photodynamic therapy, which
insult the microvascularisation of the pleura and the bronchial
stump, rendering them more susceptible to infection (Sterman
et al, 1999).
The previously published studies using the combination of
cytoreductive surgery and ITCH for the treatment of pleural
malignancies reported interesting results of survival and of
locoregional disease control. The Netherlands Cancer Institute
reported just one out of 11 local recurrence in mesothelioma
patients and all thymoma patients were alive and free of disease
(De Bree et al, 2002). Yellin et al (2001) reported a complete
ipsilateral pleuropulmonary control in 17 out of 26 patients. The 1-,
2- and 3-year survival rates were 72, 65 and 44%, respectively
(Yellin et al, 2001). However, it is important to note that in this
study, there were only seven mesothelioma patients and 11
thymoma patients who have a completely different course as
compared to mesothelioma with a better prognosis. The median
follow-up of these two studies did not exceed 18 and 45 months,
respectively. With a higher median follow-up, we reported a higher
rate of local recurrence (13 out of 24 patients). However, the 1- and
5-year survival rates that were 74 and 27%, respectively, are
interesting as the overall median survival (21 months).
The survival results for T1 or T2 mesothelioma tumours were
significantly greater than for T3 or T4 mesothelioma tumours and
achieved a median survival of 41.3 months. This could be
explained by the surgical procedure. Pleurectomy alone or the
combination of decortication with pleurectomy are perhaps not
sufficient for T3 or T4 tumours. The disadvantage of this
procedure relates to its limited cytoreduction, especially when
the tumour invades the fissures. Extrapleural pneumonectomy
may be more indicated in patients with T3 or T4 tumours and is
currently used as a debulking procedure in some multimodality
therapy (Sterman et al, 1999). For mesothelioma patients, our 2-
and 5-year survival rates (50 and 8% respectively) compare
favourably with the survival results reported with the trimodality
therapy employing extrapleural pneumonectomy followed by
combination chemoradiotherapy (Sugarbaker et al, 1998). The
combination of cytoreductive surgery with ITCH has added to
some extent to the survival results, but, certainly, part of the
interesting survival results might be due to our strict selection
process.
Regarding patients with other malignancies, the variability and
small number of patients preclude any comprehensive conclu-
sions. Nevertheless, in this group, three patients with fibrosarcoma
are alive with no evidence of recurrence at 24, 43 and 54 months.
The tumours were T1 in two cases but T3 in one case. For
metastatic disease, two patients died from local recurrence at 6 and
20 months, but local control was obtained in one patient who died
from bone metastases at 74 months. For these diseases, local
treatment is not expected to cure patients, but local control may
cause symptomatic relief and occasionally prolong survival. No
objective preoperative and postoperative assessment of symptoms
and quality of life was carried out in this study. However,
regarding the subjective assessment conducted during the follow-
up, we noticed an improvement of quality of life with symptomatic
relief in all our patients until recurrence.
We conclude that the combination of cytoreductive surgery
(pleurectomy alone or decortication/pleurectomy) with ITCH with
MMC and/or CDDP is associated with acceptable morbidity.
Encouraging results have been achieved in a selected group of
patients regarding survival rates (unexpected long-term survival in
mesothelioma patients with T1 and T2 tumours and in fibrosarco-
ma patients). However, many problems remain to be solved:
controlled studies are necessary to evaluate clearly the benefit of
this new therapeutic approach, and standardised criteria will be
necessary (extension degree of surgical resection, type and dose of
anticancer drugs, effect of higher intrapleural temperature, etc.).
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